CD274 and non-small cell lung carcinoma: In a phase III keynote-024 trial, patients with advanced NSCLC and high PD-L1 expression (Tumor Proportion Score, TPS ≥ 50%) who were treated with pembrolizumab monotherapy had longer progression-free survival than patients treated with platinum-based chemotherapy (30).